Cargando…

Association between obesity and trastuzumab-related cardiac toxicity in elderly patients with breast cancer

PURPOSE: Trastuzumab can improve the prognosis for patients with breast cancer, but its related cardiac toxicity is concerning. This study aimed to identify the risk factors associated with trastuzumab-related cardiac toxicity in elderly patients with HER2-positive breast cancer. PATIENTS AND METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Hai-Yan, Yin, Bei-Bei, Jia, Dan-Yan, Hou, Ying-Long
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Clinical Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668040/ https://www.ncbi.nlm.nih.gov/pubmed/29108307 http://dx.doi.org/10.18632/oncotarget.17808

Ejemplares similares

Cardiac toxicity of trastuzumab in elderly patients with breast cancer
por: Denegri, Andrea, et al.
Publicado: (2016)

Early cardiac toxicity following adjuvant radiotherapy of left-sided breast cancer with or without concurrent trastuzumab
por: Cao, Lu, et al.
Publicado: (2015)

Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study
por: Bengala, C, et al.
Publicado: (2006)

Trastuzumab-associated cardiac events in the Persephone trial
por: Earl, Helena M, et al.
Publicado: (2016)

Biomarkers of Trastuzumab-Induced Cardiac Toxicity in HER2- Positive Breast Cancer Patient Population
por: Grela-Wojewoda, Aleksandra, et al.
Publicado: (2022)

Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer
por: Clayton, A J, et al.
Publicado: (2004)

Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients
por: Cheng, Y C, et al.
Publicado: (2010)

Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer
por: Palmieri, Carlo, et al.
Publicado: (2015)

Anti-HER-2 therapy following severe trastuzumab-induced cardiac toxicity
por: Sadek, Ibrahim, et al.
Publicado: (2017)

Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring
por: Jones, A L, et al.
Publicado: (2009)

Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2021)

Influenza vaccination in breast cancer patients during subcutaneous trastuzumab in adjuvant setting
por: Joona, Therse Björkin, et al.
Publicado: (2020)

Paraoxonase-1 Activity in Breast Cancer Patients Treated With Doxorubicin With or Without Trastuzumab
por: Thompson, Elizabeth W., et al.
Publicado: (2021)

Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study
por: Vici, Patrizia, et al.
Publicado: (2014)

A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy
por: Hurvitz, Sara A., et al.
Publicado: (2013)

Vinorelbine with or without Trastuzumab in Metastatic Breast Cancer: A Retrospective Single Institution Series
por: Stravodimou, Athina, et al.
Publicado: (2014)

Acute toxicity of intraoperative radiotherapy and external beam-accelerated partial breast irradiation in elderly breast cancer patients
por: Jacobs, D. H. M., et al.
Publicado: (2018)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
por: Yang, Jiangping, et al.
Publicado: (2022)

Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2 – a prospective study
por: Piotrowski, Grzegorz, et al.
Publicado: (2012)

A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study
por: Lidbrink, Elisabet, et al.
Publicado: (2018)

Trastuzumab beyond progression in HER2-positive advanced breast cancer: The Royal Marsden experience
por: Waddell, T, et al.
Publicado: (2011)

Safety survey on infusion reaction and cardiac dysfunction when switching from reference trastuzumab (HERCEPTIN(®)) to biosimilar trastuzumab (Trastuzumab‑NK) in the treatment of HER2‑positive breast cancer
por: Abe, Tomoya, et al.
Publicado: (2023)

Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china
por: Xu, Qiaoping, et al.
Publicado: (2021)

Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer
por: Gori, S, et al.
Publicado: (2004)

Cardiac side effects of trastuzumab in breast cancer patients – single centere experiences
por: Huszno, Joanna, et al.
Publicado: (2013)

Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group
por: Mackey, J.R., et al.
Publicado: (2008)

More than 9 years of continuous trastuzumab treatment in metastatic breast cancer without cardiac toxicity: a case report and literature review
por: Badulescu, Florin, et al.
Publicado: (2014)

Trastuzumab deruxtecan for breast cancer
Publicado: (2022)

Evaluation of Left Ventricular Ejection Fractions in Breast Cancer Patients Undergoing Long-Term Trastuzumab Treatment
por: Sun, Yong, et al.
Publicado: (2016)

Systemic toxicities of trastuzumab‐emtansine predict tumor response in HER2+ metastatic breast cancer
por: Tang, Shou‐Ching, et al.
Publicado: (2021)

Risks of trastuzumab‐related cardiotoxicity in breast cancer patients in Taiwan
por: Chang, Wei‐Ting, et al.
Publicado: (2021)

Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates
por: Lu, Dan, et al.
Publicado: (2014)

Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
por: de Oliveira Taveira, Mateus, et al.
Publicado: (2017)

Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT)
por: Sella, Tal, et al.
Publicado: (2022)

Signal Detection of Adverse Events Associated with Trastuzumab in a Cohort of Elderly Patients with Breast Cancer
por: Polychronopoulou, Efstathia, et al.
Publicado: (2022)

Neoadjuvant Pyrotinib plus Trastuzumab and Chemotherapy for Stage I–III HER2‐Positive Breast Cancer: A Phase II Clinical Trial
por: Xuhong, Juncheng, et al.
Publicado: (2020)

Alterations in mRNA profiles of trastuzumab-resistant Her-2-positive breast cancer
por: Zhao, Bin, et al.
Publicado: (2018)

PTX3 from vascular endothelial cells contributes to trastuzumab-induced cardiac complications
por: Xu, Zhifei, et al.
Publicado: (2023)

Trastuzumab and Gemcitabine in Pretreated HER2 Overexpressing Metastatic Breast Cancer Patients: Retrospective Analysis of Our Series
por: Di Lauro, Vincenzo, et al.
Publicado: (2012)

The influence of steroid receptor status on the cardiotoxicity risk in HER2-positive breast cancer patients receiving trastuzumab
por: Huszno, Joanna, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_dieqtsc5ir8d5s9used09aumqu